Table 3.
Summary of clinical cases.
| Age | Sex | ECOG PS | Diagnosis (Date) | Site of Primary GCTB | Surgery | Rec. Date | Treat. Management | Malignant Transformation (Date/Surgery or Biopsy) | Treat. | Evolution | Subsequent CHT Lines | FU/D | Time to MT (Months) | OS from GCTB Diagnosis (Months) | OS from MT (Months) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 | 29 | F | 0 | 17 July | Right femur | Curettage and bone grafts |
18 February | Neoadj denosumab (7 cycles) |
18 July Extraarticular resection: high-grade fibroblastic osteosarcoma |
ISG/OS-2 | PD | I: IFO II: GEM.TXT III: PAZO |
D 22 January |
9 | 53 | 43 |
| Pt 2 | 48 | M | 0 | 16 November | Right tibia | Curettage and bone grafts |
20 October | Neoadj denosumab (6 cycles) |
21 February Extraarticular resection: malignant transformation of GCTB |
EURO BOSS |
NED | - | FU 21 December |
51 | 64 | 13 |
| Pt 3 | 20 | F | 0 | 10 September | Left femur | Resection of the femoral head, curettage and bone grafts |
11 March | Biopsy | 11 June Biopsy: high-grade osteosarcoma G3 with aberrant expression of beta-HCG |
ISG/OS-1 | PD | - | D 11 November |
9 | 14 | 5 |
GCTB: giant cell tumour of bone; Pt: patient; PS: performance status; CHT: chemotherapy; Rec. date: recurrence date; Treat: treatment; Treat. Management: treatment management; FU: follow-up; D: death; OS: overall survival; F: female; M: male; ISG/OS-2: Italian Sarcoma Group/Osteosarcoma-2 [49]; IFO: ifosfamide [50]; GEM-TXT: gemcitabine-taxotere [51]; PAZO: pazopanib [52,53]; EUROBOSS: EUROpean Bone Over 40 Sarcoma Study [54]; ISG/OS-1: Italian Sarcoma Group/Osteosarcoma-1 [59]; PD: progression disease; NED: no evidence of disease; neoadj: neoadjuvant; MT: malignant transformation.